Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.

Crowe JS, Roberts KJ, Carlton TM, Maggiore L, Cubitt MF, Clare S, Harcourt K, Reckless J, MacDonald TT, Ray KP, Vossenkämper A, West MR.

Sci Rep. 2018 Mar 21;8(1):4941. doi: 10.1038/s41598-018-23277-7.

2.

Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial.

Bath PM, Scutt P, Blackburn DJ, Ankolekar S, Krishnan K, Ballard C, Burns A, Mant J, Passmore P, Pocock S, Reckless J, Sprigg N, Stewart R, Wardlaw JM, Ford GA; PODCAST Trial Investigators.

PLoS One. 2017 Jan 17;12(1):e0164608. doi: 10.1371/journal.pone.0164608. eCollection 2017.

3.

Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST).

Scutt P, Blackburn D, Krishnan K, Ballard C, Burns A, Ford GA, Mant J, Passmore P, Pocock S, Reckless J, Sprigg N, Stewart R, Wardlaw JM, Bath PM.

Trials. 2015 Nov 7;16:509. doi: 10.1186/s13063-015-1033-2.

4.

Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids.

Blackburn DJ, Krishnan K, Fox L, Ballard C, Burns A, Ford GA, Mant J, Passmore P, Pocock S, Reckless J, Sprigg N, Stewart R, Wardlaw J, Bath PM.

Trials. 2013 Nov 22;14:401. doi: 10.1186/1745-6215-14-401.

5.

Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity.

Lean M, Brosnahan N, McLoone P, McCombie L, Higgs AB, Ross H, Mackenzie M, Grieve E, Finer N, Reckless J, Haslam D, Sloan B, Morrison D.

Br J Gen Pract. 2013 Feb;63(607):e115-24. doi: 10.3399/bjgp13X663073.

6.

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.

Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JP, Bakhai A.

Pharmacoeconomics. 2013 Apr;31(4):269-75. doi: 10.1007/s40273-013-0036-7. Review.

PMID:
23512147
7.

Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus.

Li L, Ambegaonkar BM, Reckless JP, Jick S.

Eur J Prev Cardiol. 2014 Jul;21(7):855-65. doi: 10.1177/2047487313481752. Epub 2013 Mar 4.

PMID:
23460659
8.

Anaesthetic impairment of immune function is mediated via GABA(A) receptors.

Wheeler DW, Thompson AJ, Corletto F, Reckless J, Loke JC, Lapaque N, Grant AJ, Mastroeni P, Grainger DJ, Padgett CL, O'Brien JA, Miller NG, Trowsdale J, Lummis SC, Menon DK, Beech JS.

PLoS One. 2011 Feb 24;6(2):e17152. doi: 10.1371/journal.pone.0017152.

9.

Primary prevention of cardiovascular disease.

Reckless JP.

BMJ. 2011 Jan 25;342:d201. doi: 10.1136/bmj.d201. No abstract available.

PMID:
21266415
10.

Benefits and risks around glycaemic control in diabetes: where are we now?

Reckless J, Robinson A.

Int J Clin Pract. 2010 Jul;64(8):1001-3. doi: 10.1111/j.1742-1241.2010.02368.x. No abstract available.

PMID:
20642697
11.

Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.

Reckless J, Davies G, Tunceli K, Hu XH, Brudi P.

Value Health. 2010 Sep-Oct;13(6):726-34. doi: 10.1111/j.1524-4733.2010.00742.x. Epub 2010 Jun 7.

12.

Counterweight - counter-cost, counter-loss.

Lean ME, Reckless JP, Finer N, McCombie L.

Int J Clin Pract. 2010 May;64(6):828-9. doi: 10.1111/j.1742-1241.2010.02400.x. No abstract available.

PMID:
20518958
13.

How much will Incretin Mimetics contribute to hyperglycaemia management?

Reckless JP.

Int J Clin Pract. 2010 Mar;64(4):418-20. doi: 10.1111/j.1742-1241.2010.02339.x. No abstract available.

PMID:
20456185
14.

Long-term cost-effectiveness of weight management in primary care.

Trueman P, Haynes SM, Felicity Lyons G, Louise McCombie E, McQuigg MS, Mongia S, Noble PA, Quinn MF, Ross HM, Thompson F, Broom JI, Laws RA, Reckless JP, Kumar S, Lean ME, Frost GS, Finer N, Haslam DW, Morrison D, Sloan B; Counterweight Project Team.

Int J Clin Pract. 2010 May;64(6):775-83. doi: 10.1111/j.1742-1241.2010.02349.x. Epub 2010 Mar 29.

PMID:
20353431
15.

Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors.

Fox DJ, Reckless J, Lingard H, Warren S, Grainger DJ.

J Med Chem. 2009 Jun 11;52(11):3591-5. doi: 10.1021/jm900133w.

PMID:
19425597
16.

Engaging patients, clinicians and health funders in weight management: the Counterweight Programme.

Counterweight Project Team, McQuigg M, Brown JE, Broom JI, Laws RA, Reckless JP, Noble PA, Kumar S, McCombie EL, Lean ME, Lyons GF, Mongia S, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N, Haslam DW, Ross HM, Hole DJ, Radziwonik S.

Fam Pract. 2008 Dec;25 Suppl 1:i79-86. doi: 10.1093/fampra/cmn081. Epub 2008 Nov 27.

PMID:
19042914
17.

Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.

Brudi P, Reckless JP, Henry DP, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO.

Cardiology. 2009;113(2):89-97. doi: 10.1159/000172795. Epub 2008 Nov 15.

PMID:
19018143
18.

The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change.

McQuigg M, Brown JE, Broom J, Laws RA, Reckless JP, Noble PA, Kumar S, McCombie EL, Lean ME, Lyons FG, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N, Haslam DW, Ross HM, Hole DJ, Radziwonik S.

Obes Res Clin Pract. 2008 Mar;2(1):I-II. doi: 10.1016/j.orcp.2008.01.002.

PMID:
24351674
19.

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.

Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C.

Int J Clin Pract. 2008 Apr;62(4):539-54. doi: 10.1111/j.1742-1241.2008.01697.x. Epub 2008 Feb 11.

PMID:
18266852
20.

The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro.

Beech JS, Wheeler DW, Reckless J, Grant AJ, Price J, Mastroeni P, Grainger DJ, Menon DK.

J Neuroimmunol. 2007 Mar;184(1-2):198-208. Epub 2007 Feb 7.

PMID:
17289163
21.

Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.

Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F; POLARIS study investigators.

Atherosclerosis. 2007 Oct;194(2):e154-64. Epub 2007 Jan 16.

PMID:
17229426
22.

Diabetes and lipid lowering: where are we?

Reckless JP.

BMJ. 2006 May 13;332(7550):1103-4. No abstract available.

23.

Statin-induced myositis: a commonly encountered or rare side effect?

Mukhtar RY, Reckless JP.

Curr Opin Lipidol. 2005 Dec;16(6):640-7. Review.

PMID:
16276242
24.

Broad spectrum chemokine inhibitors related to NR58-3.14.3.

Grainger DJ, Reckless J, Fox DJ.

Mini Rev Med Chem. 2005 Sep;5(9):825-32. Review.

PMID:
16178724
25.

Broad-spectrum chemokine inhibition reduces vascular macrophage accumulation and collagenolysis consistent with plaque stabilization in mice.

Reckless J, Tatalick L, Wilbert S, McKilligin E, Grainger DJ.

J Vasc Res. 2005 Nov-Dec;42(6):492-502. Epub 2005 Sep 7.

PMID:
16155365
26.

Empowering primary care to tackle the obesity epidemic: the Counterweight Programme.

McQuigg M, Brown J, Broom J, Laws RA, Reckless JP, Noble PA, Kumar S, McCombie EL, Lean ME, Lyons GF, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N, Ross HM, Hole DJ; Counterweight Project Team.

Eur J Clin Nutr. 2005 Aug;59 Suppl 1:S93-100; discussion S101.

PMID:
16052202
27.

Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.

Mukhtar R, Reckless JP.

Diabet Med. 2005 Jul;22 Suppl 3:6-10. Review. No abstract available.

PMID:
15960775
28.

Inherited pericentric inversion (X)(p11.4q11.2) associated with delayed puberty and obesity in two brothers.

Talaban R, Sellick GS, Spendlove HE, Howell R, King C, Reckless J, Newbury-Ecob R, Houlston RS.

Cytogenet Genome Res. 2005;109(4):480-4.

PMID:
15905641
29.

Pitavastatin.

Mukhtar RY, Reid J, Reckless JP.

Int J Clin Pract. 2005 Feb;59(2):239-52. Review.

PMID:
15854203
30.

Identification of 3-(acylamino)azepan-2-ones as stable broad-spectrum chemokine inhibitors resistant to metabolism in vivo.

Fox DJ, Reckless J, Wilbert SM, Greig I, Warren S, Grainger DJ.

J Med Chem. 2005 Feb 10;48(3):867-74.

PMID:
15689171
32.

The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.

Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP.

Atherosclerosis. 2004 May;174(1):141-9.

PMID:
15135263
33.

Tools for anti-inflammatory drug design: in vitro models of leukocyte migration.

Frow EK, Reckless J, Grainger DJ.

Med Res Rev. 2004 May;24(3):276-98. Review.

PMID:
14994365
34.
35.

Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo.

Grainger DJ, Reckless J.

Biochem Pharmacol. 2003 Apr 1;65(7):1027-34. Review.

PMID:
12663038
36.

Risk for myopathy with statin therapy in high-risk patients.

Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, Stein EA.

Arch Intern Med. 2003 Mar 10;163(5):553-64. Review.

PMID:
12622602
37.

Fluvastatin.

Lawrence JM, Reckless JP.

Expert Opin Pharmacother. 2002 Nov;3(11):1631-41. Review.

PMID:
12437496
39.

Neuroprotection in ischemia-reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor.

Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SC, Menon DK.

J Cereb Blood Flow Metab. 2001 Jun;21(6):683-9.

PMID:
11488537
40.

Actos (pioglitazone): a new treatment for type 2 diabetes.

Lawrence JM, Reckless JP.

Hosp Med. 2001 Jul;62(7):411-6. Review.

PMID:
11480129
41.

Difficult insulinoma.

Lawrence JM, Smith T, Iles D, Reckless JP.

J R Soc Med. 2001 Jul;94(7):349-50. No abstract available.

43.

A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions.

Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainger DJ.

J Vasc Res. 2001 May-Jun;38(3):256-65.

PMID:
11399898
44.

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.

Ballantyne CM, Pazzucconi F, Pintó X, Reckless JP, Stein E, McKenney J, Bortolini M, Chiang YT.

Clin Ther. 2001 Feb;23(2):177-92.

PMID:
11293552
45.

Pioglitazone.

Lawrence JM, Reckless JP.

Int J Clin Pract. 2000 Nov;54(9):614-8. Review.

PMID:
11220991
46.

Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease.

Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ.

Ann Rheum Dis. 2000 Nov;59(11):904-9.

47.

Cost-effectiveness of statins.

Reckless JP.

Curr Opin Lipidol. 2000 Aug;11(4):351-6. Review.

PMID:
10945715
48.
49.

Monocyte chemoattractant protein-1 but not tumor necrosis factor-alpha is correlated with monocyte infiltration in mouse lipid lesions.

Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainger DJ.

Circulation. 1999 May 4;99(17):2310-6.

PMID:
10226098
50.

Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.

Lye M, Valacio R, Reckless JP, Ghosh AK, Findlay IN, Ghosh MK, Passmore AP, Fulcher RA.

Coron Artery Dis. 1998;9(9):583-90.

PMID:
9861520

Supplemental Content

Loading ...
Support Center